Dr. Dreicer on Abiraterone and Enzalutamide in Prostate Cancer
March 24th 2017Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).
Enhanced Recovery Program Improves Outcomes After Colorectal Cancer Surgery
February 3rd 2017The adoption of enhanced recovery after surgery protocols can improve not only the outcomes of patients after a procedure but can also reduce hospital costs, as has been seen in an ERAS program in colorectal cancer at the University of Virginia Health System.
Studies Challenge Common Treatment Strategies in Prostate Cancer
May 8th 2014Two recent studies have raised questions about current trends in prostate cancer (PC) treatment, one supporting the employment of a little-used strategy-direct treatment of the primary tumor in men who have metastatic PC at diagnosis